Following an abbreviated submission
tipranavir 250mg soft capsules (Aptivus ) in combination with low dose ritonavir are accepted for restricted use within NHS Scotland for combination antiretroviral treatment of HIV-1 infection in highly pre-treated adolescents 12 years of age or older with virus resistant to multiple protease inhibitors.
The marketing authorisation for tipranavir states that it should only be used as part of an active combination antiretroviral regimen in patients with no other therapeutic options. In adult patients the Scottish Medicines Consortium has restricted tipranavir to patients with a tipranavir mutation score of less than 4 and this restriction should also apply to this licence extension covering adolescents 12 years of age and older. Tipranavir is listed in the British National Formulary for Children for the treatment of HIV infection.
Download detailed advice50KB (PDF)
- Medicine name:
- tipranavir (Aptivus) 250mg soft capsule
- SMC ID:
- HIV-1 infection in highly pre-treated adolescents 12 years of age or older with virus resistant to multiple protease inhibitors
- Pharmaceutical company
- Boehringer Ingelheim Ltd
- BNF chapter
- Submission type
- Date advice published:
- 08 February 2010